Volunteering For An Alzheimer's Disease Clinical Trial

Warner, a clinical trial volunteer, describes his participation in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Caring for an Alzheimer's patient

A moving story of an 85 year-old man caring for his 75 year-old wife, who is an Alzheimer's patient.

The Face of Alzheimer's Disease

A daughter's perspective upon learning that her mother has Alzheimer's Disease.

Benefits of exercise for older adults supported by study

It's well-known that exercise is crucial for good health no matter how old you are.

Clinical Trials - About

A4 Trial

Alzheimer’s-related brain changes take place years, even decades before symptoms appear. Scientists are hopeful that if they can intervene at the earliest possible stage, they may be able to stop or slow the progression of the disease. The A4 Study will see if researchers can prevent memory loss and possibly the progression to Alzheimer’s disease by treating older individuals who may be at higher risk .


There is growing evidence that poor regulation of insulin may make it difficult for the brain to function optimally and may contribute to the development of Alzheimer’s. The SNIFF study will help us find out whether a type of insulin, when administered as a nasal spray, can improve memory in adults with a mild memory impairment or Alzheimer’s disease.

NCA&T Study

Alzheimer’s disease occurs more often in African Americans than in Caucasians. By studying many people with Alzheimer’s disease, researchers at North Carolina A&T State University and the John P. Hussman Institute for Human Genomics hope to find genes (inherited material) that may cause Alzheimer’s disease in African Americans. The goals of this research study are to find the genetic causes of Alzheimer’s disease and to improve Alzheimer’s tests and treatments for African Americans.


MINDSET is a Phase III clinical research program evaluating an investigational medication, RVT-101, for mild-to-moderate Alzheimer’s disease. It has already been tested in 13 clinical trials, including a 684-subject study where it was found to have statistically significant benefits on cognition and ability to perform daily tasks as compared to donepezil alone. The MINDSET study aims to confirm these results. If approved, this will be the first new Alzheimer’s drug on the market in 17 years.


Visit The Brain Health Registry

In the United States...

  • 5.4 million Americans have Alzheimer’s — double the number since 1980 — two thirds are women.
  • 16 million are expected to have Alzheimer’s by 2050
  • Sixth leading cause of death among all adults and only one with no treatment, prevention or cure.
  • Deaths due to Alzheimer’s are increasing, while mortality rates for cancer and heart disease are decreasing
  • In 2012, direct costs of care for Alzheimer’s patient was estimated to be $200 billion. African Americans bear at least 30 percent of these costs despite being less than 14 percent of the U.S. population
  • 1 in 7 Alzheimer’s patients live alone, increasing risk for accidents, malnutrition and other problems
  • Research Pipeline: 312 therapies for Alzheimer’s disease are in clinical trials
^ Back to Top